Systemic lupus erythematosus (SLE): sustained clinical benefit and reduction in severe flares with Stelara® (ustekinumab) #EULAR2019
The Janssen Pharmaceutical Companies of Johnson & Johnson presented this week results of two analyses from a Phase 2 study of Stelara®*(ustekinumab) in systemic lupus erythematosus (SLE). The studies highlight not only the sustained clinical benefit of ustekinumab – an anti-interleukin (IL) IL-12/23 p40 neutralising monoclonal antibody – on SLE
Continua a leggere